In this piece, we discuss the Top 10 Stocks Under $5 That Could Triple.
Ongoing market commentary has seen divided views on the broader outlook, especially after the recent escalations in the Middle East.
At one end of the spectrum, until a few weeks ago, there was optimism about the broader market’s performance this year. Based on a Reuters poll of 44 strategists reported on February 24, 2026, the S&P 500 was projected to show 10% growth from the February close this year, reaching 7,500 by the end of the year. Strategists anticipated strong earnings and steady economic growth, dismissing concerns related to trade policy and artificial intelligence-driven disruption. If strategists are correct about their projection, this year would potentially mark the fourth straight year of gains for the broader market.
On the other hand, Jim Cramer incorporated ongoing market disruptions into his comments made on March 20, 2026. While shedding light on the near-term outlook, he cautions that volatility seen over the past week amid geopolitical tensions and rising oil prices could cause market weakness to persist. Amid escalating conflict involving the U.S., Israel, and Iran, alongside surging crude prices, equities remain under pressure, he added.
Against this dynamic backdrop, our list offers a peek at companies analysts believe could deliver massive gains for investors. Thus, let’s now jump to our list of the top 10 stocks under $5 that could triple.
Methodology
To curate our list of the top 10 stocks under $5 that could triple, we relied on a screener to identify companies trading below $5. Next, we filtered for stocks with upside potential of more than 300% while ensuring each stock had significant analyst coverage. Finally, we ranked the stocks in ascending order based on their upside potential.
Note: All data was sourced on March 19, 2026.
“Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).”
10. Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) earns a place on our top 10 stocks under $5 that could triple.
As of March 19, 2026, 83% of covering analysts maintain bullish ratings for Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) with a consensus price target of $40.00, indicating 2,073.91% upside despite share price pressure.
Nevertheless, D. Boral Capital took a more cautious approach by downgrading Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH)’s stock from “Buy” to “Hold” after the company announced a reverse stock split. These developments temper the confidence shown by investors, according to the firm. D. Boral Capital further added that although these moves do not change the underlying fundamentals, they have historically been followed by continued pressure on equities and are frequently linked to poor share price performance, often reflecting efforts to preserve compliance with exchange listing requirements.
This event follows the company’s filing of a 1-for-20 reverse stock split on March 4, 2026. Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) shares will continue to trade under the “RVPH” symbol on a split-adjusted basis, with no change in proportional shareholder control.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is a clinical-stage biopharmaceutical company focusing on the development of therapies for CNS, respiratory, and metabolic disorders. The company’s primary candidate, brilaroxazine, is designed to address neuropsychiatric indications through proprietary chemical genomics platforms.
9. TScan Therapeutics, Inc. (NASDAQ:TCRX)
TScan Therapeutics, Inc. (NASDAQ:TCRX) is among the top 10 stocks under $5 that could triple.
As of March 19, 2026, analysts maintain a strong sentiment regarding TScan Therapeutics, Inc. (TCRX). With over 80% of analysts holding a “Buy” rating, the stock is projected to have a 455.56% potential upside based on the consensus price target.
Developments regarding TScan Therapeutics, Inc. (NASDAQ:TCRX)’s pipeline have helped strengthen the confidence of analysts at Wedbush amid ongoing momentum in the cell therapy space.
A broader update is scheduled for the second half of 2026, with the firm highlighting data from its Phase 1 ALLOHA trial’s Cohort C, which is expected in Q2 2026. Wedbush noted that upcoming conferences like ASH and EHA will likely serve as occasions for these updates, further adding that the company’s near-term outlook will hinge on these developments.
On March 5, 2026, Wedbush reiterated its “Outperform” rating and increased its price target for TScan Therapeutics, Inc. (NASDAQ:TCRX) from $4 to $5. Analysts emphasized the company’s continuous development, especially as it expands its clinical programs.
TScan Therapeutics, Inc. (NASDAQ:TCRX) is a clinical-stage biotechnology company focused on developing T-cell receptor therapies aimed at malignancies and other serious diseases, utilizing its platform to discover novel antigens and reduce off-target interactions.
8. Sagimet Biosciences Inc. (NASDAQ:SGMT)
Sagimet Biosciences Inc. (NASDAQ:SGMT) earns a place on our list of the top 10 stocks under $5 that could triple.
As of March 19, 2026, 91% of analysts remain bullish on Sagimet Biosciences Inc. (NASDAQ:SGMT). The stock boasts a consensus price target of $27.50, indicating an upside of 437.27%.
On March 11, 2026, in its fourth-quarter and full-year 2025 financial results update, Sagimet Biosciences Inc. (NASDAQ:SGMT) emphasized ongoing pipeline momentum, which strengthened investor confidence. In the second half of 2026, the company plans to commence a Phase 2 trial in F4 MASH patients. This development comes after the company successfully completed a Phase 1 pharmacokinetic trial, assessing denifanstat in combination with resmetirom, with no significant adverse effects.
Its ongoing first-in-human Phase 1 trial for TVB-3567, which targets acne, is another example of Sagimet Biosciences Inc.’s (NASDAQ:SGMT) progress. Additionally, Ascletis, a partner, published positive Phase 3 acne data and obtained NDA acceptance in China.
In terms of finances, Sagimet Biosciences Inc. (NASDAQ:SGMT) concluded 2025 with $113.1 million in cash, $39.1 million in R&D costs, and a $51.0 million net loss as opposed to a $45.6 million loss in 2024.
Importantly, HC Wainwright reaffirmed its “Buy” rating that same day, demonstrating confidence in the stock.
Sagimet Biosciences Inc. (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company developing FASN inhibitors, such as denifanstat, to address metabolic and dermatological disorders, particularly for MASH and acne treatments.
7. Altimmune, Inc. (NASDAQ:ALT)
Altimmune, Inc. (NASDAQ:ALT) earns a spot on our list of the top 10 stocks under $5 that could triple.
On March 16, 2026, H.C. Wainwright noted growing optimism around pipeline expansion and upside potential by raising the price target for Altimmune, Inc. (NASDAQ:ALT) from $12 to $25, while maintaining a “Buy” rating on the stock. Altimmune, Inc. (NASDAQ:ALT)’s strategic focus on its MASH program has strengthened the investment narrative amid growing attention toward treatments for metabolic and liver diseases.
H.C. Wainwright analysts highlighted Altimmune, Inc. (NASDAQ:ALT)’s focus on its intended MASH pivotal program, while also incorporating additional value from pemvidutide in alcohol-related liver disease and alcohol use disorder into their model. Significant unmet need and promising clinical and preclinical liver results were identified by the firm as key drivers.
Meanwhile, Pemvidutide’s differentiation as it enters Phase 3 trials, the upcoming Phase 2 RECLAIM AUD topline data in Q3 2026, and a $340 million pro-forma cash runway are factors bolstering the company’s outlook, according to analysts at B. Riley, who, on March 6, 2026, lowered the firm’s price target to $13 from $18 while maintaining a “Buy” rating.
Altimmune, Inc. (NASDAQ:ALT) is a clinical-stage biopharmaceutical company engaged in developing peptide-based therapeutics, such as pemvidutide for obesity and NASH, and HepTcell, an immunotherapy designed to achieve a functional cure for hepatitis B.
6. Biomea Fusion, Inc. (NASDAQ:BMEA)
Biomea Fusion, Inc. (NASDAQ:BMEA) earns a place on our list of the top 10 stocks under $5 that could triple.
As of March 19, 2026, almost 88% of covering analysts keep bullish ratings on the stock. With a consensus price target of $6.00, indicating a potential upside of 415.02%, analyst sentiment remains positive toward Biomea Fusion, Inc. (NASDAQ:BMEA).
On March 14, 2026, Biomea Fusion, Inc. (NASDAQ:BMEA) reported positive 52-week follow-up findings from its Phase II COVALENT-111 study of icovamenib in type 2 diabetes at the ATTD conference in Barcelona. This clinical progress serves as the foundation for analyst optimism.
Of the 267 patients assessed in the randomized, placebo-controlled trial, 163 completed at least 80% of their dosage before a clinical hold. The findings showed statistically significant declines in HbA1c, with severe insulin-deficient individuals experiencing reductions of up to 1.50% at Week 52. Efficacy was further supported by improvements in beta-cell activity and long-lasting glucose control nine months after therapy. There were no significant side effects or treatment-related discontinuations, and the therapy was well tolerated.
Biomea Fusion, Inc. (NASDAQ:BMEA) formulates covalent small-molecule therapeutics aimed at treating cancers and metabolic disorders, with its primary candidate, icovamenib, targeting diabetes and BMF-219 addressing oncogenic signaling in genetically characterized tumors.
While we acknowledge the potential of BMEA to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BMEA and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the Top 5 Stocks Under $5 That Could Triple.
Disclosure: None. Follow Insider Monkey on Google News.
